Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 220 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Long Coronavirus Disease 2019 (Covid19) Clear all
Not yet recruiting Not applicable Interventional

Fareon Open Label Device Clinical Trial

NCT07600320
View directory record Official record
Conditions
Cognitive Dysfunction, Acquired Brain Injury, Traumatic Brain Injury
Interventions
Fareon device
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Not yet recruiting Phase 2 Interventional

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

NCT07597902
View directory record Official record
Conditions
Post-acute Sequelae of COVID-19, Long COVID
Interventions
Valacyclovir, Celecoxib, Paxlovid, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Recruiting No phase listed Observational

Long-Term Study of COVID-19 Infection and Long COVID

NCT07781501
View directory record Official record
Conditions
SARS CoV-2 Post-Acute Sequelae
Interventions
This study is observational. Only patients who have previously tested positive for SARS-CoV-2 infection or are experiencing ongoing symptoms.
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Completed Not applicable Interventional

Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth

NCT04385901
View directory record Official record
Conditions
SARS-CoV 2, SARS Pneumonia
Interventions
Therapy Intervention
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 13, 2026, 5:40 PM EDT
Completed Phase 2 Interventional

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

NCT04604704
View directory record Official record
Conditions
Covid19, Long COVID-19, Post-COVID-19 Syndrome
Interventions
Naltrexone, NAD+
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 13, 2026, 5:40 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

NCT05421208
View directory record Official record
Conditions
Post-acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS), Long COVID, SARS CoV 2 Infection
Interventions
Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls, Levels of inflammatory cytokine ( IL-6) in controls, Effect on inflammation after chronic PNS stimulation
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Withdrawn Phase 3 Interventional

REVERSE-Long COVID-19 With Baricitinib Study

NCT05858515
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Baricitinib 4 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

NCT05633407
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
Efgartigimod, Placebo
Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
La Jolla, California • Palo Alto, California • Glenview, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 13, 2026, 5:40 PM EDT
Recruiting Not applicable Interventional

Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome

NCT05977179
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, Fatigue
Interventions
Dietary intervention to mitigate Post-Acute COVID-19 Syndrome, Attention Control
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
50 Years to 94 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol

NCT06404086
View directory record Official record
Conditions
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Interventions
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block for COVID-induced Parosmia

NCT06253806
View directory record Official record
Conditions
COVID-19-Induced Parosmia
Interventions
Stellate Ganglion Block, Placebo Sham Injection
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 13, 2026, 5:40 PM EDT
Recruiting No phase listed Observational

A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae

NCT06006884
View directory record Official record
Conditions
COVID-19
Interventions
Bronchoscopies and Bronchoalveolar Lavages (BALs), Chest Tomography (CT), Electrocardiogram (ECG), Pulmonary function tests (PFTs), 6 minute walk test (6MWT)
Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Recruiting Not applicable Interventional

Long COVID Brain Fog: Cognitive Rehabilitation Trial

NCT06095297
View directory record Official record
Conditions
Long COVID, Brain Fog, Cognitive Impairment, Cognitive Dysfunction, Post-Acute COVID-19 Syndrome
Interventions
Processing Speed Training, In-lab Instrumental Activities of Daily Living Training, In-lab Brain Health Training, Transfer Package, Follow Up Phone Calls, Vocational Rehabilitation, Peer Mentoring, Reaction Time Training, Trans-auricular Vagus Nerve Stimulation: High Intensity, Trans-auricular Vagus Nerve Stimulation: Low Intensity
Behavioral · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Withdrawn Early Phase 1 Interventional

The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

NCT05371288
View directory record Official record
Conditions
COVID-19
Interventions
NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 13, 2026, 5:40 PM EDT
Completed Phase 2 Interventional Results available

Effect of Lithium Therapy on Long COVID Symptoms

NCT05618587
View directory record Official record
Conditions
Long COVID
Interventions
Lithium, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 13, 2026, 5:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Physiology of Long COVID-19 and the Impact of Cardiopulmonary Rehabilitation on Quality-of-Life and Functional Capacity

NCT05566483
View directory record Official record
Conditions
Post-acute Sequelae of SARS-CoV-2 Infection
Interventions
Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 13, 2026, 5:40 PM EDT
Completed Not applicable Interventional Results available

Vagus Nerve Stimulation as Treatment for Long Covid

NCT05608629
View directory record Official record
Conditions
Long COVID, Chronic Fatigue Syndrome
Interventions
Transcutaneous Non-Invasive Vagus Nerve Stimulation
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Up to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 13, 2026, 5:40 PM EDT
Completed Phase 1 Interventional

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

NCT05638620
View directory record Official record
Conditions
Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent, Post-Acute COVID-19, Post-Acute COVID-19 Infection, SARS-CoV2 Infection, Post Acute Sequelae of COVID-19, Dysautonomia, Dysautonomia Like Disorder, Dysautonomia Orthostatic Hypotension Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Post-COVID-19 Syndrome
Interventions
stellate ganglion block with 0.5% bupivacaine
Drug
Lead sponsor
Jonathann Kuo, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 13, 2026, 5:40 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 13, 2026, 5:40 PM EDT
Completed Not applicable Interventional

RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)

NCT06404060
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Personalized Cardiopulmonary Rehabilitation, Education
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

NCT06161688
View directory record Official record
Conditions
Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
Interventions
Ensitrelvir, Placebo
Drug · Other
Lead sponsor
Timothy Henrich
Other
Eligibility
18 Years to 69 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Completed Not applicable Interventional

Effect of Daily Walnut Consumption on Memory in Subjects With Long-COVID

NCT07429903
View directory record Official record
Conditions
Long-COVID, Brain Fog, Cognition, Memory
Interventions
whole food - walnuts
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 13, 2026, 5:40 PM EDT
Terminated Phase 1 Interventional

A Trial of NT-I7 in COVID-19 (SPESELPIS)

NCT04501796
View directory record Official record
Conditions
COVID-19
Interventions
Double-Blind NT-I7, Double-Blind Placebo
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
19 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 13, 2026, 5:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 13, 2026, 5:40 PM EDT